Pelacarsen Setback Removes Key Pipeline Catalyst for Novartis

What happened

Novartis's pelacarsen, its Lp(a)-lowering candidate, has hit a setback according to a recent report, shaking the competitive landscape for Lp(a) therapies. The DeepValue master report had identified the pelacarsen Lp(a)HORIZON readout as a major near-term catalyst, with its failure listed as a thesis breaker because it would remove a large non-oncology upside leg and break premium-multiple support. The news article frames this as bad for Novartis but potentially beneficial for Eli Lilly, which also has an Lp(a) drug in development, shifting the multibillion-dollar race. At the time of the master report, Novartis was already under pressure from Entresto generic erosion, with H1 2026 sales down 2% constant currency and margin falling to 32.6%, so this pipeline failure adds to the earnings transition burden. The market had been pricing Novartis as a premium pipeline story at 23.1x earnings, but with one of three key H2 readouts now apparently negative, the valuation looks less justified and the downside scenarios become more probable.

Implication

For investors, the loss of pelacarsen as a near-term upside driver materially weakens the investment case for Novartis. The stock's premium valuation relied on successful pipeline events to offset ongoing Entresto erosion, and this setback removes a major non-oncology growth opportunity. With one of the three key H2 readouts now negative, the probability of the bear case (flat sales, margin compression, no major catalyst) rises, potentially pushing fair value toward the $128 bear scenario from the prior $158 base. Even if other catalysts like Pluvicto approval and remibrutinib MS data succeed, the total addressable market expansion from pelacarsen is gone, limiting upside. Investors should consider selling or reducing positions, or at least wait for a much lower entry point near $140 or below, as the risk-reward has deteriorated.

Thesis delta

The original thesis was that Novartis could justify a premium multiple through H2 2026 pipeline catalysts, including pelacarsen. The reported failure of pelacarsen removes one of the three key readouts and breaks the non-oncology upside leg. This shifts the balance toward the bear scenario, increasing downside risk and suggesting that the stock's current valuation may be too high; the thesis is materially weakened and the rating likely moves from WAIT to more defensive.